Retrophin Founder Said Probed on Possible Securities Wrongs
This article is for subscribers only.
Retrophin Inc. founder Martin Shkreli, replaced last year as chief executive officer of the biopharmaceutical company, is under investigation by U.S. prosecutors in Brooklyn, New York, for possible securities law violations, according to a person familiar with the matter.
Shkreli, a one-time short-seller who started New York-based Retrophin at 28, left his CEO post in September. Investors claimed in later lawsuits against him and the company that he distributed stock without the consent of shareholders.